What is ARS Pharmaceuticals, Inc (SPRY) stock price today?

ARS Pharmaceuticals, Inc (SPRY) currently trades at $8.26 per share. The stock has a market capitalization of $788.42M and a P/E ratio of —x.

Is SPRY stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, ARS Pharmaceuticals, Inc has a Smart Value Score of 18/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 0.76.

What is ARS Pharmaceuticals, Inc's revenue and earnings?

ARS Pharmaceuticals, Inc has trailing twelve-month (TTM) revenue of $84.28M with profit margins of -203.30%. Earnings per share (EPS) is $-1.74.

Is ARS Pharmaceuticals, Inc financially healthy?

ARS Pharmaceuticals, Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 0.76 places it in the distress.

SPRY

ARS Pharmaceuticals, Inc

NASDAQ: SPRY · HEALTHCARE · BIOTECHNOLOGY

$8.26

+5.36% today

Updated 2026-04-30

Market cap

$788.42M

P/E ratio

—

P/S ratio

9.36x

EPS (TTM)

$-1.74

Dividend yield

—

52W range

$7 – $19

Volume

1.5M

Market cap

$788.42M

P/E ratio

—

P/S ratio

9.36x

EPS (TTM)

$-1.74

Dividend yield

—

52W range

$7 – $19

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

6.0

Quality

2.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

0.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$26.71

+223.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z 0.76 — distress zone

- Thin margins at -203.30%

- Negative free cash flow $-43.48M

- Revenue declining -67.60% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.32M	$30000.00	$89.15M	$84.28M	$84.28M
Net income	$-34.68M	$-54.37M	$8.00M	$-171.30M	$-41.32M
EPS	—	—	—	—	$-1.74
Free cash flow	$-40.28M	$-59.44M	$12.98M	$-171.21M	$-43.48M
Profit margin	-2,635.41%	-181,216.67%	8.97%	-203.25%	-203.30%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SPRY	$788.42M	18	5.3	2.0	5.0	6.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

ARS Pharmaceuticals, Inc trades at $8.26. Our Smart Value Score of 18/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 0.76, it sits in the distress. TTM revenue stands at $84.28M. with profit margins at -203.30%.

Frequently asked questions

What is ARS Pharmaceuticals, Inc's stock price?

ARS Pharmaceuticals, Inc (SPRY) trades at $8.26.

Is ARS Pharmaceuticals, Inc overvalued?

Smart Value Score 18/100 (Grade F, Strong Sell).

What is the price target of ARS Pharmaceuticals, Inc (SPRY)?

The analyst target price is $26.71, representing +223.4% upside from the current price of $8.26.

What is ARS Pharmaceuticals, Inc's revenue?

TTM revenue is $84.28M.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

0.76 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

ars-pharma.com

Quick metrics

P/S ratio9.36x

ROE-92.30%

Beta0.93

50D MA$8.49

200D MA$10.72

Shares out0.10B

Float0.04B

Short ratio—

Avg volume1.5M

Performance

1 week-4.34%

1 month-1.12%

3 months-22.31%

YTD-31.85%

1 year—

3 years—

5 years—

Compare

SPRY vs LLY →SPRY vs JNJ →SPRY vs ABBV →Stock screener →